Knight Net Income from 2010 to 2026
| GUD Stock | CAD 5.89 0.03 0.51% |
Net Income | First Reported 2012-09-30 | Previous Quarter -12.6 M | Current Value -3.8 M | Quarterly Volatility 19.9 M |
Check Knight Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Knight Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 64.1 M, Interest Expense of 9.2 M or Selling General Administrative of 26.3 M, as well as many indicators such as Price To Sales Ratio of 1.59, Dividend Yield of 0.31 or PTB Ratio of 1.11. Knight financial statements analysis is a perfect complement when working with Knight Therapeutics Valuation or Volatility modules.
Knight | Net Income |
Evaluating Knight Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Knight Therapeutics's fundamental strength.
Latest Knight Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Knight Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Knight Therapeutics financial statement analysis. It represents the amount of money remaining after all of Knight Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Knight Therapeutics' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Knight Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 4.33 M | 10 Years Trend |
|
Net Income |
| Timeline |
Knight Net Income Regression Statistics
| Arithmetic Mean | 44,147,295 | |
| Geometric Mean | 26,794,904 | |
| Coefficient Of Variation | 128.07 | |
| Mean Deviation | 48,065,633 | |
| Median | 18,560,000 | |
| Standard Deviation | 56,540,001 | |
| Sample Variance | 3196.8T | |
| Range | 155.8M | |
| R-Value | (0.86) | |
| Mean Square Error | 888.3T | |
| R-Squared | 0.74 | |
| Slope | (9,628,426) | |
| Total Sum of Squares | 51148.3T |
Knight Net Income History
About Knight Therapeutics Financial Statements
Knight Therapeutics investors utilize fundamental indicators, such as Net Income, to predict how Knight Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Income | 3.9 M | 3.7 M | |
| Net Income Applicable To Common Shares | 5 M | 5.2 M | |
| Net Income Per Share | 0.05 | 0.05 | |
| Net Income Per E B T | 1.90 | 2.00 |
Other Information on Investing in Knight Stock
Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.